<code id='0AD03DBA5B'></code><style id='0AD03DBA5B'></style>
    • <acronym id='0AD03DBA5B'></acronym>
      <center id='0AD03DBA5B'><center id='0AD03DBA5B'><tfoot id='0AD03DBA5B'></tfoot></center><abbr id='0AD03DBA5B'><dir id='0AD03DBA5B'><tfoot id='0AD03DBA5B'></tfoot><noframes id='0AD03DBA5B'>

    • <optgroup id='0AD03DBA5B'><strike id='0AD03DBA5B'><sup id='0AD03DBA5B'></sup></strike><code id='0AD03DBA5B'></code></optgroup>
        1. <b id='0AD03DBA5B'><label id='0AD03DBA5B'><select id='0AD03DBA5B'><dt id='0AD03DBA5B'><span id='0AD03DBA5B'></span></dt></select></label></b><u id='0AD03DBA5B'></u>
          <i id='0AD03DBA5B'><strike id='0AD03DBA5B'><tt id='0AD03DBA5B'><pre id='0AD03DBA5B'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:778
          Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT
          Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

          WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

          “Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

          advertisement

          There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          President Biden's budget: Here's what you might have missed
          President Biden's budget: Here's what you might have missed

          PresidentBidenspeaksatacampaigneventinAtlantathismonth.MeganVarner/GettyImagesWASHINGTON—PresidentBi

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          What a koala virus tells us about the human genome

          ADOBEThehumangenomeisnotentirelyhuman.Some8%ofourDNA,infact,originatedinviruses,remnantsofancientsin